Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 1,004,852 | 1,032,135 | 984,168 | 1,002,549 | 1,009,763 |
| Cost of Goods | 666,060 | 675,068 | 666,436 | 718,305 | 660,742 |
| Gross Profit | 338,792 | 357,067 | 317,732 | 284,244 | 349,021 |
| Operating Expenses | 205,053 | 257,001 | 243,499 | 452,236 | 232,358 |
| Operating Income | 133,799 | 100,134 | 74,669 | -167,687 | 117,405 |
| Interest Expense | 25,403 | 29,967 | 27,884 | 28,234 | 30,284 |
| Other Income | -21,196 | 1,251 | -10,807 | -20,870 | 4,120 |
| Pre-tax Income | 87,200 | 71,418 | 35,978 | -216,791 | 91,241 |
| Income Tax | 31,644 | 18,725 | 10,100 | -3,044 | 20,946 |
| Net Income Continuous | 55,556 | 52,693 | 25,878 | -213,747 | 70,295 |
| Minority Interests | 1,134 | 367 | 409 | 68 | 1,017 |
| Net Income | $54,422 | $52,326 | $25,469 | $-213,815 | $69,278 |
| EPS Basic Total Ops | 1.11 | 1.06 | 0.50 | -4.20 | 1.34 |
| EPS Basic Continuous Ops | 1.13 | 1.07 | 0.51 | -4.15 | 1.37 |
| EPS Diluted Total Ops | 1.10 | 1.06 | 0.50 | -4.17 | 1.33 |
| EPS Diluted Continuous Ops | 1.12 | 1.07 | 0.51 | -4.13 | 1.36 |
| EPS Diluted Before Non-Recurring Items | 2.43 | 3.12 | 2.34 | 2.66 | 2.59 |
| EBITDA(a) | $218,963 | $219,641 | $195,033 | $149,418 | $205,603 |